{"id":745324,"date":"2016-10-03T07:00:00","date_gmt":"2016-10-03T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/"},"modified":"2025-11-07T01:25:38","modified_gmt":"2025-11-07T06:25:38","slug":"merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/","title":{"rendered":"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced that new data from the company\u2019s chronic hepatitis C<br \/>\n      virus (HCV) clinical development programs will be presented at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE+2016&amp;index=1&amp;md5=fafdfd1e915323f5cf7f9ed817b4c4c6\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup> 2016<\/a>. Fifteen scientific abstracts,<br \/>\n      including seven oral and eight poster presentations, will highlight<br \/>\n      findings from Merck\u2019s HCV clinical development programs. The data<br \/>\n      include evaluations of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg<br \/>\n      tablets and the company\u2019s investigational MK-3682B (MK-3682<sup>1<\/sup>\/grazoprevir<sup>2<\/sup>\/rusazvir)<br \/>\n      in a broad range of patients with chronic HCV infection. The Liver<br \/>\n      Meeting<sup>\u00ae<\/sup> 2016 will take place in Boston, MA, from November<br \/>\n      11-15, 2016.\n    <\/p>\n<p>\n      \u201cMerck has been a part of the fight against chronic hepatitis C<br \/>\n      infection for more than 30 years, and that fight continues. Chronic<br \/>\n      hepatitis C is a complex infectious disease that affects tens of<br \/>\n      millions of patients globally, each with their own personal<br \/>\n      circumstances, co-morbidities and challenges,\u201d said Dr. Eliav Barr,<br \/>\n      senior vice president, global clinical development, infectious diseases<br \/>\n      and vaccines, Merck Research Laboratories. \u201cAt AASLD this year,<br \/>\n      researchers will share data from numerous studies that are underway to<br \/>\n      better understand the potential of ZEPATIER and our investigational<br \/>\n      medicines in diverse patient populations.\u201d\n    <\/p>\n<p>\n      Key presentations at The Liver Meeting<sup>\u00ae<\/sup> 2016 will include:\n    <\/p>\n<p>\n      <b>ZEPATIER (elbasvir and grazoprevir)<\/b>\n    <\/p>\n<p>\n      <i>Saturday, November 12<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        HCV reinfection and injecting risk behavior following<br \/>\n        elbasvir\/grazoprevir treatment in patients on opioid agonist therapy: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105688&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=CO-STAR&amp;index=2&amp;md5=1df91054c997a7f21d5edae2d1fe5b76\" rel=\"nofollow\"><br \/>\n<i>CO-STAR<\/i><br \/>\n<\/a><br \/>\n        Three Year Follow-up Study (Poster presentation, Abstract #871, 2:00<br \/>\n        p.m. \u2013 7:30 p.m. EDT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        High Efficacy in Patients With Chronic Hepatitis C Virus (HCV)<br \/>\n        Genotype (GT)1b Infection Treatment With Elbasvir\/Grazoprevir for 12<br \/>\n        Weeks: An Integrated Analysis (Poster presentation, Abstract #874,<br \/>\n        2:00 p.m. &#8211; 7:30 p.m. EDT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Concomitant Proton Pump Inhibitor Use Does Not Reduce the Efficacy of<br \/>\n        Elbasvir\/Grazoprevir (Poster presentation, Abstract #869, 2:00 p.m. \u2013<br \/>\n        7:30 p.m. EDT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Elbasvir\/Grazoprevir (EBR\/GZR) Does Not Worsen Renal Function in<br \/>\n        Patients With Hepatitis C Virus (HCV) Infection and Pre-existing Renal<br \/>\n        Disease (Poster presentation, Abstract #889, 2:00 p.m. \u2013 7:30 p.m. EDT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Final Results from Phase 3 Portion in Phase 2\/3 Study of Elbasvir \/<br \/>\n        Grazoprevir in Hepatitis C Genotype 1 Infected Japanese Patients<br \/>\n        (Poster presentation, Abstract #851, 2:00 p.m. \u2013 7:30 p.m. EDT)\n      <\/li>\n<\/ul>\n<p>\n      <i>Sunday, November 13<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Efficacy and Safety of Elbasvir\/Grazoprevir in Treatment-Na\u00efve<br \/>\n        Subjects with Chronic HCV GT1, GT4 and GT6 Infection (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02251990&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=C-CORAL&amp;index=3&amp;md5=4b5e2ed7c43608261268df38e31b72a1\" rel=\"nofollow\"><br \/>\n<i>C-CORAL<\/i><br \/>\n<\/a>):<br \/>\n        A Phase III Randomized Multinational Clinical Trial (Oral<br \/>\n        presentation, Abstract #76, 3:45 p.m. \u2013 4:00 p.m. EDT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02601573&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=C-ISLE&amp;index=4&amp;md5=e8e23a1629ce6b28f32a84aac09cdd53\" rel=\"nofollow\"><br \/>\n<i>C-ISLE<\/i><br \/>\n<\/a>:<br \/>\n        Grazoprevir\/Elbasvir plus Sofosbuvir in Treatment-na\u00efve and<br \/>\n        Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or<br \/>\n        16 weeks (Oral presentation, Abstract #74, 3:15 p.m. \u2013 3:30 p.m. EDT)\n      <\/li>\n<\/ul>\n<p>\n      <b>INVESTIGATIONAL TRIPLE-THERAPY REGIMEN<\/b>\n    <\/p>\n<p>\n      <i>Sunday, November 13<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Safety and Efficacy of the Fixed-Dose Combination Regimen of<br \/>\n        MK-3682\/Grazoprevir\/MK-8408 With or Without Ribavirin in Non-cirrhotic<br \/>\n        or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B<br \/>\n        of <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332707&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=C-CREST+1&amp;index=5&amp;md5=5cafc060f3b20af4254c01e2c90794f1\" rel=\"nofollow\"><br \/>\n<i>C-CREST<br \/>\n        1<\/i><br \/>\n<\/a> &amp; <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332720&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=2&amp;index=6&amp;md5=7a79ecf6b941bc94c8673df775a64154\" rel=\"nofollow\"><br \/>\n<i>2<\/i><br \/>\n<\/a>)<br \/>\n        (Oral presentation, Abstract #110, 5:00 p.m. \u2013 5:15 p.m. EDT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        High Sustained Virologic Response (SVR) Rates in Patients with Chronic<br \/>\n        HCV GT1, 2 or 3 Infection Following 16 Weeks of<br \/>\n        MK-3682\/Grazoprevir\/MK-8408 Plus Ribavirin After Failure of 8 Weeks of<br \/>\n        Therapy (Part C of <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332707&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=C-CREST+1&amp;index=7&amp;md5=4e36539f3e5e84393ef7a2c5672dfb94\" rel=\"nofollow\"><br \/>\n<i>C-CREST<br \/>\n        1<\/i><br \/>\n<\/a> &amp; <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332720&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=2&amp;index=8&amp;md5=0b6a12a025131d17545275006066a89a\" rel=\"nofollow\"><br \/>\n<i>2<\/i><br \/>\n<\/a>)<br \/>\n        (Oral presentation, Abstract #112, 5:30 p.m. \u2013 5:45 p.m. EDT)\n      <\/li>\n<\/ul>\n<p>\n      <i>Monday, November 14<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Safety and Efficacy of the Fixed-Dose Combination Regimen of<br \/>\n        MK-3682\/Grazoprevir\/MK-8408 in Cirrhotic or Non-cirrhotic Patients<br \/>\n        with Chronic HCV GT1 Infection who Previously Failed a Direct-acting<br \/>\n        Antiviral Regimen (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02613403&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=C-SURGE&amp;index=9&amp;md5=f8dd9942b1d64e3d09ca2fd78a426d37\" rel=\"nofollow\"><br \/>\n<i>C-SURGE<\/i><br \/>\n<\/a>)<br \/>\n        (Oral presentation, Abstract #193, 3:00 p.m. \u2013 3:15 p.m. EDT)\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a complete list of abstract titles at<br \/>\n      the meeting, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;index=10&amp;md5=08071933d6afff621fbfa5c23a3e6b50\" rel=\"nofollow\">http:\/\/www.aasld.org\/events-professional-development\/liver-meeting<\/a>.\n    <\/p>\n<p>\n      <b>About ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg Tablets<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a fixed-dose combination product containing elbasvir, a HCV<br \/>\n      NS5A inhibitor, and grazoprevir, an HCV NS3\/4A protease inhibitor. In<br \/>\n      the United States, ZEPATIER is indicated with or without ribavirin (RBV)<br \/>\n      for treatment of chronic HCV GT1 or 4 infection in adults. ZEPATIER is<br \/>\n      not indicated to treat chronic HCV GT3 or GT6 infection. ZEPATIER was<br \/>\n      approved in the United States on January 28, 2016 and is also approved<br \/>\n      in the European Union, Canada, Japan, Australia, Saudi Arabia, Israel<br \/>\n      and Switzerland, with additional regulatory approvals anticipated.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ZEPATIER<\/b>\n    <\/p>\n<p>\n      ZEPATIER is not for use in patients with moderate or severe hepatic<br \/>\n      impairment (Child Pugh B or C). ZEPATIER is also not for use with<br \/>\n      organic anion transporting polypeptides 1B1\/3 (OATP1B1\/3) inhibitors<br \/>\n      (e.g., atazanavir, darunavir, lopinavir, saquinavir, tipranavir,<br \/>\n      cyclosporine), strong cytochrome P450 3A (CYP3A) inducers (e.g.,<br \/>\n      carbamazepine, phenytoin, rifampin, St. John\u2019s Wort), and efavirenz. If<br \/>\n      ZEPATIER is administered with RBV, healthcare professionals should refer<br \/>\n      to the prescribing information for RBV as the contraindications,<br \/>\n      warnings and precautions, adverse reactions and dosing for RBV also<br \/>\n      apply to this combination regimen.\n    <\/p>\n<p>\n      Elevations of alanine transaminase (ALT) to greater than 5 times the<br \/>\n      upper limit of normal (ULN) occurred in 1% of subjects, generally at or<br \/>\n      after treatment week 8. These late ALT elevations were typically<br \/>\n      asymptomatic and most resolved with ongoing or completion of therapy.<br \/>\n      Healthcare professionals should perform hepatic lab testing on patients<br \/>\n      prior to therapy, at treatment week 8, and as clinically indicated. For<br \/>\n      patients receiving 16 weeks of therapy, additional hepatic lab testing<br \/>\n      should be performed at treatment week 12.\n    <\/p>\n<p>\n      Patients should be instructed to consult their healthcare professional<br \/>\n      without delay if they have onset of fatigue, weakness, lack of appetite,<br \/>\n      nausea and vomiting, jaundice or discolored feces. Healthcare providers<br \/>\n      should consider discontinuing ZEPATIER if ALT levels remain persistently<br \/>\n      greater than 10 times ULN. ZEPATIER should be discontinued if ALT<br \/>\n      elevation is accompanied by signs or symptoms of liver inflammation or<br \/>\n      increasing conjugated bilirubin, alkaline phosphatase, or international<br \/>\n      normalized ratio.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER with certain drugs may lead to adverse<br \/>\n      reactions or reduced therapeutic effect due to drug interactions.<br \/>\n      Certain strong CYP3A inhibitors may increase the plasma concentration of<br \/>\n      ZEPATIER, leading to possibly clinically significant adverse reactions.<br \/>\n      Moderate CYP3A inducers may decrease the plasma concentration of<br \/>\n      ZEPATIER, leading to reduced therapeutic effect and possible development<br \/>\n      of resistance. Coadministration of ZEPATIER with these drugs is not<br \/>\n      recommended. Physicians should consult the Prescribing Information for<br \/>\n      potential drug interactions.\n    <\/p>\n<p>\n      In subjects receiving ZEPATIER for 12 weeks, the most commonly reported<br \/>\n      adverse reactions of all intensity (greater than or equal to 5% in<br \/>\n      placebo-controlled trials) were fatigue, headache and nausea. In<br \/>\n      subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly<br \/>\n      reported adverse reactions of moderate or severe intensity (greater than<br \/>\n      or equal to 5%) were anemia and headache.\n    <\/p>\n<p>\n      <b>Selected Dosage and Administration Information for ZEPATIER (elbasvir<br \/>\n      and grazoprevir)<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a single tablet taken once daily. The recommended dosing is<br \/>\n      12 or 16 weeks with or without RBV, depending on HCV genotype, prior<br \/>\n      treatment history and, for patients with genotype 1a infection, presence<br \/>\n      of certain baseline NS5A resistance-associated polymorphisms. See<br \/>\n      Prescribing Information for ZEPATIER for specific dosage regimens and<br \/>\n      durations. Refer to RBV prescribing information for RBV dosing and<br \/>\n      dosage modifications when ZEPATIER is given with RBV. To determine<br \/>\n      dosage regimen and duration of ZEPATIER for genotype 1a patients,<br \/>\n      testing for the presence of virus with one or more baseline NS5A<br \/>\n      resistance-associated polymorphisms at positions 28, 30, 31, or 93 is<br \/>\n      recommended prior to initiating treatment.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For more than 30 years, Merck has been at the forefront of the response<br \/>\n      to the HCV epidemic. Merck\u2019s chronic HCV clinical development programs<br \/>\n      have included more than 135 clinical trials in approximately 40<br \/>\n      countries and have enrolled nearly 10,000 participants. As part of our<br \/>\n      longstanding leadership in infectious diseases, Merck collaborates with<br \/>\n      the scientific and patient communities to develop and deliver innovative<br \/>\n      solutions to support people living with chronic HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=11&amp;md5=b8500bab88498cb3b747750c927cda54\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=Twitter&amp;index=12&amp;md5=40f722de08915b582accdffd63194745\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=Facebook&amp;index=13&amp;md5=1447ea0f32f829783c4ba3ebb7c93f62\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=YouTube&amp;index=14&amp;md5=cee7602311acc9c58cfd8ffdcbf746fb\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=15&amp;md5=ff642d3b9bc0adfa39ceab37bf28f87a\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=16&amp;md5=b5d714803fafbd26206cf0791df3fa75\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZEPATIER (elbasvir and<br \/>\n      grazoprevir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;index=17&amp;md5=23625e2f8eed98c1cd5a5db6c4d86bf9\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and the Patient Information for ZEPATIER at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;esheet=51431437&amp;newsitemid=20161003005479&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;index=18&amp;md5=f977b9ca29fa7bce28f6566c72b96448\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>\n        <\/td>\n<td>\n          \u00a0\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignr\">\n          <sup>1<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          MK-3682 is an HCV nucleotide analogue NS5B polymerase inhibitor\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignr\">\n          <sup>2<\/sup>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignl\">\n          Rusazvir (MK-8408) is an HCV NS5A inhibitor\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161003005479r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-740-1903<br \/>Ian McConnell,        908-740-1921<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company\u2019s chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting\u00ae 2016 . Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Merck\u2019s HCV clinical development programs. The data include evaluations of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets and the company\u2019s investigational MK-3682B (MK-3682 1 \/grazoprevir 2 \/rusazvir) in a broad range of patients with chronic HCV infection. The Liver Meeting \u00ae 2016 will take place in Boston, MA, from November 11-15, 2016. \u201cMerck has been a part of the fight against chronic hepatitis C infection for more than 30 years, and that fight continues. Chronic hepatitis C is a complex infectious disease that affects tens of millions of patients globally, each with their own personal circumstances, co-morbidities and challenges,\u201d<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289],"class_list":["post-745324","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company\u2019s chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting\u00ae 2016 . Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Merck\u2019s HCV clinical development programs. The data include evaluations of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets and the company\u2019s investigational MK-3682B (MK-3682 1 \/grazoprevir 2 \/rusazvir) in a broad range of patients with chronic HCV infection. The Liver Meeting \u00ae 2016 will take place in Boston, MA, from November 11-15, 2016. \u201cMerck has been a part of the fight against chronic hepatitis C infection for more than 30 years, and that fight continues. Chronic hepatitis C is a complex infectious disease that affects tens of millions of patients globally, each with their own personal circumstances, co-morbidities and challenges,\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\\\/\",\"name\":\"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-03T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company\u2019s chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting\u00ae 2016 . Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Merck\u2019s HCV clinical development programs. The data include evaluations of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets and the company\u2019s investigational MK-3682B (MK-3682 1 \/grazoprevir 2 \/rusazvir) in a broad range of patients with chronic HCV infection. The Liver Meeting \u00ae 2016 will take place in Boston, MA, from November 11-15, 2016. \u201cMerck has been a part of the fight against chronic hepatitis C infection for more than 30 years, and that fight continues. Chronic hepatitis C is a complex infectious disease that affects tens of millions of patients globally, each with their own personal circumstances, co-morbidities and challenges,\u201d","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:38+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/","name":"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-03T07:00:00+00:00","dateModified":"2025-11-07T06:25:38+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-on-zepatier-elbasvir-and-grazoprevir-and-chronic-hepatitis-c-clinical-development-programs-at-the-liver-meeting-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present New Data on ZEPATIER\u2122 (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting\u00ae 2016"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b6167590-7734-48e8-a96e-35f678441d27","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745324\/revisions"}],"predecessor-version":[{"id":3674731,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745324\/revisions\/3674731"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745324"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}